{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:54:09Z","timestamp":1772175249402,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","bbmt.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.bbmt.2014.06.032","type":"journal-article","created":{"date-parts":[[2014,6,27]],"date-time":"2014-06-27T22:30:48Z","timestamp":1403908248000},"page":"1654-1659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Bortezomib for Refractory Autoimmunity in Pediatrics"],"prefix":"10.1016","volume":"20","author":[{"given":"Pooja","family":"Khandelwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Grimley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonata","family":"Jodele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra J.","family":"Filipovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.06.032_bib1","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.bbmt.2008.07.006","article-title":"Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation","volume":"14","author":"Page","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.032_bib2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.bmt.1705641","article-title":"Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients","volume":"39","author":"Sanz","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.032_bib3","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.bbmt.2011.10.024","article-title":"Complications of transplant for nonmalignant disorders: autoimmune cytopenias, opportunistic infections, and PTLD","volume":"18","author":"Dvorak","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.032_bib4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bmt.1702011","article-title":"Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation","volume":"24","author":"Horn","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.032_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.2004.05138.x","article-title":"Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases","volume":"127","author":"O'Brien","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2014.06.032_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bbmt.2014.06.032_bib7","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1084\/jem.20040168","article-title":"Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W mice","volume":"199","author":"Hoyer","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.bbmt.2014.06.032_bib8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/TP.0b013e3182911739","article-title":"Proteasome inhibition profoundly affects activated human B cells","volume":"95","author":"Mulder","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2014.06.032_bib9","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21414","article-title":"Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies","volume":"104","author":"Ludwig","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2014.06.032_bib10","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/ard.2010.133256","article-title":"Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma","volume":"70","author":"Frohlich","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bbmt.2014.06.032_bib11","first-page":"475","article-title":"Bortezomib for refractory antibody-mediated cardiac allograft rejection","author":"Eckman","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1016\/j.bbmt.2014.06.032_bib12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/MOT.0b013e328330f304","article-title":"Proteasome inhibition for antibody-mediated rejection","volume":"14","author":"Everly","year":"2009","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.bbmt.2014.06.032_bib13","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2014.06.032_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/TP.0b013e31823f7eea","article-title":"Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients","volume":"93","author":"Morrow","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2014.06.032_bib15","article-title":"Bortezomib in kidney transplantation","author":"Raghavan","year":"2010","journal-title":"J\u00a0Transplant"},{"key":"10.1016\/j.bbmt.2014.06.032_bib16","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1517\/13543784.2011.618494","article-title":"Clinical and investigational use of proteasome inhibitors for transplant rejection","volume":"20","author":"Sadaka","year":"2011","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1016\/j.bbmt.2014.06.032_bib17","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/TP.0b013e3181a4b91b","article-title":"Abrogation of anti-HLA antibodies via proteasome inhibition","volume":"87","author":"Trivedi","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2014.06.032_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/TP.0b013e3181c6ff8d","article-title":"Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection","volume":"89","author":"Walsh","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2014.06.032_bib19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/MOT.0b013e328348c0e5","article-title":"Proteasome inhibitor treatment of antibody-mediated allograft rejection","volume":"16","author":"Woodle","year":"2011","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.bbmt.2014.06.032_bib20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1399-3046.2011.01543.x","article-title":"Proteasome inhibitor therapy for antibody-mediated rejection","volume":"15","author":"Woodle","year":"2011","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2014.06.032_bib21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2014.06.032_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.smim.2007.12.002","article-title":"Plasma cell development: from B-cell subsets to long-term survival niches","volume":"20","author":"Fairfax","year":"2008","journal-title":"Semin Immunol"},{"key":"10.1016\/j.bbmt.2014.06.032_bib23","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/TP.0b013e3181ff87b1","article-title":"Protective immunity remains intact after antibody removal by means of proteasome inhibition","volume":"90","author":"Everly","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl","key":"10.1016\/j.bbmt.2014.06.032_bib24","first-page":"S71","article-title":"Laboratory evaluation and transfusion support of patients with autoimmune hemolytic anemia","volume":"125","author":"Reardon","year":"2006","journal-title":"Am J Clin Pathol"}],"updated-by":[{"DOI":"10.1016\/j.bbmt.2015.11.014","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000}}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114003991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114003991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T21:53:39Z","timestamp":1538517219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879114003991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1083879114003991"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.06.032","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.bbmt.2015.11.014","asserted-by":"object"}]},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib for Refractory Autoimmunity in Pediatrics","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}